Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Help & FAQ
Dansk
English
Home
Hospitals/departments
Researchers
Research output
Activities
Prizes
Search by expertise, name or affiliation
Role of viruses in asthma
Tuomas Jartti,
Klaus Bønnelykke
, Varpu Elenius, Wojciech Feleszko
Copenhagen Prospective Studies on Asthma in Childhood
Paediatrics
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Role of viruses in asthma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Airway Epithelial Barrier
16%
Airway Microbiome
16%
Anti-respiratory Syncytial Virus
16%
Asthma
100%
Asthma Development
33%
Asthma Exacerbation
33%
Asthma Treatment
16%
Atopic Asthma
33%
Breathing Difficulties
16%
Bronchiolitis
16%
Causative Agents
16%
CDHR3
16%
Common Cold
16%
Corticosteroids
16%
Environmental Exposure
16%
Environmental Risk Factors
16%
Fish Oil
16%
Genotype
16%
Illness
16%
Inflammation
16%
Inflammatory Environment
16%
Inflammatory Mechanisms
16%
Interferon Response
16%
Monoclonal Antibody
16%
Nutritional Deficiency
16%
Oil Increase
16%
Omalizumab
16%
Palivizumab
16%
Personal Risk Factors
16%
Recurrent Wheeze
16%
Respiratory Syncytial Virus
50%
Respiratory Viral Infection
16%
Rhinovirus
100%
Risk Factors
16%
Risk Genes
16%
Specific Risk
16%
Unique Mechanism
16%
Viral Factors
16%
Viral Illness
16%
Virus
100%
Virus Infection
16%
Vitamin D
16%
Wheezing
33%
Pharmacology, Toxicology and Pharmaceutical Science
Allergic Asthma
22%
Asthma
100%
Bronchiolitis
11%
Disease
22%
Dyspnea
11%
Environmental Exposure
11%
Fish Oil
11%
Human Respiratory Syncytial Virus
44%
Human Rhinovirus
11%
Infectious Agent
11%
Inflammation
11%
Interferon
11%
Microbiome
11%
Monoclonal Antibody
11%
Nutritional Deficiency
11%
Omalizumab
11%
Palivizumab
11%
Rhinovirus
66%
Viral Respiratory Tract Infection
11%
Virus Infection
11%
Vitamin D
11%
Wheezing
33%
Immunology and Microbiology
Allergic Asthma
28%
Asthma
100%
Asthma Exacerbation
28%
Bronchiolitis
14%
Human Respiratory Syncytial Virus
57%
Human Rhinovirus
14%
Infectious Agent
14%
interferon
14%
Microbiome
14%
Monoclonal Antibody
14%
Omalizumab
14%
Palivizumab
14%
Rhinovirus
85%
Viral Disease
42%